1. miRNAs involved in drug resistance in pancreatic cancer.

Name	Expression	Gene(s) regulated	Effect	Drug(s) involved	Reference
inh: inhibited genes dependent on miRNA expression; exp: overexpressed genes dependent on miRNA expression.
MiR-21	Overexpressed	FasL, PDCD4, PTEN (inh), Bcl2 (exp)	Inhibition of apoptotic and tumor suppressor genes	Gemcitabine, 5-FU	46-48,62
MiR-29c		USP22 (exp)	Autophagic process and inhibition of apoptotic process	Gemcitabine	49,50
MiR-155		DCK, ROS detoxification genes (exp)	Increased anti-apoptotic activity, ROS detoxification and gemcitabine metabolism		53,54
MiR-365		SHC1 (inh), BAX (inh)	Inhibition of pro-apoptotic genes		55
MiR-429		PDCD4 (inh)	Inhibition of tumor suppressor gene		63
MiR-181c		CTGF, BIRC5, BLC2L1, YAP, TAZ (exp)	Inactivation of antitumor pathway and increased expression of chemoresistance genes	Gemcitabine, 5-FU, Paclitaxel	56
MiR-221-3p		RB1 (inh)	Inhibition of tumor suppressor gene	5-FU	58
MiR-320a		PDCD4, β-cadherin, E-cadherin (inh), fibronectin,N-cadherin, Vimentin, ZEB1, Snail2 (exp)	Induction of epithelial-mesenchymal transition and inhibition of tumor suppressor genes		60
MiR-145	Underexpressed	RPS6KB1 (inh), miRNA-155 (exp)	Inhibition of cell migration, tumor growth and metastasic process	Gemcitabine	51,52
MiR-506		SPHK1, Akt, NF-κB (exp)	Induction of tumorigenic pathway		64